Equity Insights: September 2024

Welcome to the very first edition of our Equity Insights newsletter!

The IR Department team is excited to launch this regular communication, where we will cover news from a range of ASX listed companies that caught our eye, including clients of ours. We'll also highlight interesting investing factoids and other articles that we found insightful on the topics of investing, leadership or productivity.

We hope you enjoy this edition and welcome any feedback you might have.

All the best,

Jane and the IR Department team

 

Register free for our Sydney investor event

IR Department, in partnership with Morgans and Stockhead, presents the inaugural HealthInvest 2024 summit at Kittyhawk on Wednesday September 18th, 2024.

With rapid growth and significant success underpinning a strong return in investor interest in the healthcare sector, HealthInvest 2024 will showcase some of Australia’s leading and emerging health and life sciences companies to an audience of professional and retail investors. This event will provide investors with the chance to hear directly from presenting companies, followed by networking opportunities over a drink and canapés. Register here.

PRESENTATIONS & WEBINARS

Below, you'll find a selection of webinars and videos featuring some of our clients over the last quarter, as they showcase their company updates and more.

MedAdvisor: CFO Ancila Desai spoke with Ausbiz here about their inaugural full-year profit, bolstered by the success of their Thriv platform and continued US expansion.

Pureprofile: Managing Director and CEO Martin Filz discusses the company’s Q4 FY24 results with Coffee Microcaps here.

Race Oncology: Race Oncology CEO Dr. Daniel Tillett discussed positive results from an investigator-sponsored Phase 1b/2 trial targeting AML in a Proactive video here.

Kazia: Professor Sudha Rao discusses cutting-edge breast cancer treatments, including Kazia's paxalisib, in a video interview, available here.

RECENT MEDIA HIGHLIGHTS

On the media front, check out a few key coverage highlights for our clients:

• AFR for WEHI: How this research institute turned cancer success into a $66m VC fund
• The Australian for Kinoxis: Kinoxis Therapeutics lands $14.5m from UniSuper, VCs to take dementia drug to phase b trials
• MoneyFM (Singapore) for Island: Money and Me: Where to invest in the biotech space?
• AFR and Sky News Australia for HaemaLogix: Former Liberal health minister Greg Hunt appointed to board of cancer biotech HaemaLogiX, makers of KappaMab (afr.com); ‘There will inevitably be another pandemic’: Former Health Minister Greg Hunt
• The Australian for Race Oncology: ASX Health Stocks: Combining bisantrene with decitabine effective on solid tumours

MARKET PULSE

Tech shares have performed well in the past trading week, with the S&P/ASX 200 Information Technology Index lifting 0.23%, while the S&P/ASX 200 Healthcare Index remained flat, although it was a busy week of reporting season for the sector.

Here are some tickers that have been generating buzz:

• Airtasker (ASX:ART) has dramatically cut its losses to just $0.2 million in FY24, skyrocketed free cash flow by 115%, and achieved robust growth in global markets driven by a savvy media blitz.
• Clinuvel Pharma (ASX:CUV) jumped 10% last week after announcing an annual profit of $35.6 million for FY24, marking a 16% increase from the previous year, largely driven by the growing demand for the company’s drug, Scenesse.
  

MARKET TIDBITS

To wrap it up, here are some bite-sized updates on market trends and other interesting news.

How Pfizer, Bristol Myers Squibb and Johnson & Johnson Are Confronting Patent Cliffs

The pharma industry is staring down the barrel of a widespread loss of exclusivity, with more than 190 products going off-patent between 2022 and 2030. Read more here.

Charting Four Decades of U.S. Tech IPOs

Check out this graphic by the Visual Capitalist as they visualise the number of tech IPOs on American exchanges from 1980–2023.